Issue

Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

A meta-analysis of microRNA-17 as a potential biomarker in diagnosis of colorectal cancer

https://doi.org/10.14715/cmb/2018.64.6.15
Tao Liu
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Jilin 130021, China
Libin Yin
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Jilin 130021, China
Guoqiang Yan
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Jilin 130021, China
Chao Li
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Jilin 130021, China
Lei Wang
Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Jilin 130021, China

Corresponding Author(s) : Lei Wang

leiwang1967@163.com

Cellular and Molecular Biology, Vol. 64 No. 6: Advances in mechanism and treatment strategy of cancer

Abstract

This meta-analysis was aimed to determine the diagnostic accuracy of circulating microRNA-17 for colorectal Cancer (CRC). Databases including PubMed, Embase, Web of Science, Cochrane Library and China National Knowledge Infrastructure (CNKI) were searched up to February 23, 2018 for eligible studies. Quality Assessment of Diagnostic Accuracy Studies (QUADAS) was employed to assess the quality of the included studies. Meta-analysis was performed in STATA 13.0. Ten studies with total 938 CRC patients and 638 control individuals were included in this meta-analysis. All of the included studies are of high quality. The summary estimates revealed that the pooled sensitivity is 0.75 (95% confidence interval (CI): 0.60–0.85) and the specificity is 68% (95% CI: 0.56–0.77), for the diagnosis of CRC. In addition, the area under the summary ROC curve (AUC) is 0.76. The current evidence suggests that circulating miR-17 has the potential diagnostic value for CRC. More prospective studies on the diagnostic value of circulating miR-17 for CRC are needed in the future. Together, microRNA-17 might be a novel potential biomarker in the diagnosis of colorectal cancer, and more studies are needed to highlight the theoretical strengths.

Keywords

MicroRNA-17 Colorectal cancer Diagnosis Meta-analysis.
Liu, T., Yin, L., Yan, G., Li, C., & Wang, L. (2018). A meta-analysis of microRNA-17 as a potential biomarker in diagnosis of colorectal cancer. Cellular and Molecular Biology, 64(6), 86–93. https://doi.org/10.14715/cmb/2018.64.6.15
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends”an update. Cancer Epidemiology and Prevention Biomarkers 2016; 25(1): 16-27.
  2. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. cell 2004; 116(2): 281-297.
  3. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nature reviews cancer 2006; 6(11): 857.
  4. Ng EK, Tsui NB, Lam NY et al. Presence of filterable and nonfilterable mRNA in the plasma of cancer patients and healthy individuals. Clinical chemistry 2002; 48(8): 1212-1217.
  5. Silva J, Rodriguez R, Garcia J et al. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002; 50(4): 530-534.
  6. Barbarotto E, Schmittgen TD, Calin GA. MicroRNAs and cancer: profile, profile, profile. International journal of cancer 2008; 122(5): 969-977.
  7. Lanza G, Ferracin M, Gafí R et al. mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Molecular cancer 2007; 6(1): 54.
  8. Monzo M, Navarro A, Bandres E et al. Overlapping expression of microRNAs in human embryonic colon and colorectal cancer. Cell research 2008; 18(8): 823.
  9. Ayaz L, Görür A, Yaroğlu HY, í–zcan C, Tamer L. Differential expression of microRNAs in plasma of patients with laryngeal squamous cell carcinoma: potential early-detection markers for laryngeal squamous cell carcinoma. Journal of cancer research and clinical oncology 2013; 139(9): 1499-1506.
  10. Humphreys KJ, McKinnon RA, Michael MZ. miR-18a inhibits CDC42 and plays a tumour suppressor role in colorectal cancer cells. PloS one 2014; 9(11): e112288.
  11. Fang L, Li H, Wang L et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget May 30 2014; 5(10): 2974-2987.
  12. Faltejskova P, Bocanek O, Sachlova M et al. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: evidence against their usage as biomarkers in colorectal cancer. Cancer Biomarkers 2013; 12(4-5): 199-204.
  13. Whiting PF, Rutjes AW, Westwood ME et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Annals of internal medicine 2011; 155(8): 529-536.
  14. Fu F, Jiang W, Zhou L, Chen Z. Circulating Exosomal miR-17-5p and miR-92a-3p Predict Pathologic Stage and Grade of Colorectal Cancer. Translational oncology 2018; 11(2): 221-232.
  15. Zekri A-RN, Youssef ASE-D, Lotfy MM et al. Circulating serum miRNAs as diagnostic markers for colorectal cancer. PLoS One 2016; 11(5): e0154130.
  16. Zhu J, Dong H, Zhang Q, Zhang S. Combined assays for serum carcinoembryonic antigen and microRNA"‘17-3p offer improved diagnostic potential for stage I/II colon cancer. Molecular and clinical oncology 2015; 3(6): 1315-1318.
  17. Zhang J, Raju GS, Chang DW, Lin SH, Chen Z, Wu X. Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer 2018; 124(4): 785-796.
  18. Koga Y, Yasunaga M, Takahashi A et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer prevention research 2010; 3(11): 1435-1442.
  19. Li J, Liu Y, Wang C et al. Serum miRNA expression profile as a prognostic biomarker of stage II/III colorectal adenocarcinoma. Scientific reports 2015; 5: 12921.
  20. Pan C, Yan X, Li H et al. Systematic literature review and clinical validation of circulating microRNAs as diagnostic biomarkers for colorectal cancer. Oncotarget 2017; 8(40): 68317.
  21. Kanaan Z, Roberts H, Eichenberger MR et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. Annals of surgery 2013; 258(3): 400-408.
  22. Guo X, Yao S, Zhu D, Zhao H, Xu Y. Significance of serum miRNA-17-3p in diagnosis of colon cancer. World Chinese Journal of Digestology 2014; 22(30): 4701-4704.
  23. Zhang S. The diagnostic role of CEA plus miR-17-3p detections in colon cancer, Suzhou University; 2013.
  24. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Statistics in medicine 2002; 21(11): 1525-1537.
  25. Walter S. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Statistics in medicine 2002; 21(9): 1237-1256.
  26. Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. The Annals of thoracic surgery 2005; 79(1): 16-20.
  27. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. Journal of clinical epidemiology 2003; 56(11): 1129-1135.
  28. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994: 1088-1101.
  29. Schetter AJ, Leung SY, Sohn JJ et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. Jama 2008; 299(4): 425-436.
  30. Wu WK, Law PT, Lee CW et al. MicroRNA in colorectal cancer: from benchtop to bedside. Carcinogenesis 2010; 32(3): 247-253.
  31. Chen X, Ba Y, Ma L et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell research 2008; 18(10): 997.
  32. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids”the mix of hormones and biomarkers. Nature reviews Clinical oncology 2011; 8(8): 467.
  33. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences 2008; 105(30): 10513-10518.
  34. Allen JE, El-Deiry WS. Circulating tumor cells and colorectal cancer. Current colorectal cancer reports 2010; 6(4): 212-220.
  35. Force UPST. Screening for colorectal cancer: recommendation and rationale. Annals of internal medicine 2002; 137(2): 129.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 797 Download : 379

Most read articles by the same author(s)

1 2 > >>